Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2144/000113970 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medical Malpractice Litigation Associated With Anesthesia: Result From the Lexis China Claims Database 2013 to 2022.
J Perianesth Nurs
January 2025
Department of Anesthesiology, West China Second Hospital, Sichuan University, Key Laboratory of Birth Deficits and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Renmin Nanlu, Chengdu, China. Electronic address:
Purpose: This study conducted an analysis of medical malpractice litigation associated with anesthesia from 2013 to 2022, aiming to evaluate incidents of anesthesia-related safety concerns among surgical patients. The use of data derived from medical malpractice claims provided valuable insights into potential risks associated with anesthesia, contributing to the mitigation of medical malpractice and the enhancement of patient safety.
Design: A retrospective study.
Outcomes for Children With Congenital Heart Disease Undergoing Ventricular Assist Device Implantation: An ACTION Registry Analysis.
J Am Coll Cardiol
December 2024
Division of Cardiology, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Background: There are no contemporary reports that highlight the national outcomes for children with congenital heart disease (CHD) undergoing ventricular assist device (VAD) implantation.
Objectives: This study sought to evaluate differences in VAD outcomes for children with CHD to those with non-CHD as well as those with univentricular CHD to those with biventricular CHD.
Methods: Data for CHD and non-CHD patients from the multicenter ACTION (Advanced Cardiac Therapies Improving Outcomes Network) undergoing VAD implantation from April 2018 to February 2023 were included.
Myocardial Fibroblast Activation After Acute Myocardial Infarction: A Positron Emission Tomography and Magnetic Resonance Study.
J Am Coll Cardiol
November 2024
British Heart Foundation Centre of Research Excellence, the University of Edinburgh, Edinburgh, Scotland, United Kingdom.
Background: Myocardial fibrosis is a key healing response after myocardial infarction driven by activated fibroblasts. Gallium-68-labeled fibroblast activation protein inhibitor ([Ga]-FAPI) is a novel positron-emitting radiotracer that binds activated fibroblasts.
Objectives: The aim of this study was to investigate the intensity, distribution, and time-course of fibroblast activation after acute myocardial infarction.
The Nonsyndromic Ascending Thoracic Aorta in a Population-Based Setting: A 5-Year Prospective Cohort Study.
J Am Coll Cardiol
November 2024
Elite Centre for Individualized Medicine in Arterial Disease, Odense University Hospital, Odense, Denmark; Department of Cardiothoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Background: Prospective data on the clinical course of the ascending thoracic aorta are lacking.
Objectives: This study sought to estimate growth rates of the ascending aorta and to evaluate occurrences of adverse aortic events (AAEs)-that is, thoracic aortic ruptures, type A aortic dissections, and thoracic aortic-related deaths.
Methods: In this prospective cohort study from the population-based, multicenter, randomized DANCAVAS (Danish Cardiovascular Screening trials) I and II, participants underwent cardiovascular risk assessments including electrocardiogram-gated, noncontrast computed tomography (CT) scans.
Worldwide Chronic Retrieval Experience of Helix-Fixation Leadless Cardiac Pacemakers.
J Am Coll Cardiol
December 2024
Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Background: The growing use of leadless pacemaker (LP) technology requires safe and effective solutions for retrieving and removing these devices over the long term.
Objectives: This study sought to evaluate retrieval and removal of an active helix-fixation LP studied in worldwide regulatory clinical trials.
Methods: Subjects enrolled in the LEADLESS II phase 1 investigational device exemption, LEADLESS Observational, or LEADLESS Japan trials with an attempted LP retrieval at least 6 weeks postimplantation were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!